Compare Immunovant Inc. Common Stock (IMVT) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Atlassian Corporation PLC — how do they compare? Immunovant Inc. Common Stock trades at $30.25 (market cap $6.25B), while Atlassian Corporation PLC trades at $204 (market cap $51.53B). The key difference: Atlassian Corporation PLC is far larger — about 8.2× Immunovant Inc. Common Stock's market cap, and Atlassian Corporation PLC is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Atlassian Corporation PLC for 64 Days on average.
| IMVT | TEAM | |
|---|---|---|
Market Cap | $6.25B | $51.53B |
Volume | 1,755,411 | 2,904,511 |
Sector | Health | Technology |
52-Week High | $44.96 | $203.57 |
52-Week Low | $17.03 | $57.15 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $5.35B | $51.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Atlassian (TEAM) trades at $195.67, up 0.87% with bullish technical momentum and strong analyst support. The stock shows consistent earnings beats with Q2 2026 EPS of $1.87 exceeding expectations. Revenue growth remains robust at $5.22B in 2025, though profitability challenges persist with negative net margins. Recent news highlights AI-driven growth catalysts and cloud migration success.
Outlook remains positive with 69.77% analyst buy ratings and $191.16 consensus target. Key opportunities include $140B addressable market and AI adoption, while risks involve negative profitability metrics and high valuation multiples. The stock faces execution risk in maintaining growth momentum amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
